Hepion Pharmaceuticals, Inc. (HEPA)
2025-06-30 | ||||
|---|---|---|---|---|
| Revenues | - | |||
| Research and development | 423,277 | |||
| General and administrative | 919,488 | |||
| Asset impairment loss | 402,746 | |||
| Total operating expenses | 1,745,511 | |||
| Loss from operations | -1,745,511 | |||
| Interest income (expense) | 4,866 | |||
| Inducement expense | - | |||
| Change in fair value of contingent consideration and derivative financial instruments | 698,073 | |||
| Loss before income taxes | -1,042,572 | |||
| Income tax benefit | - | |||
| Net loss | -1,042,572 | |||
| Net loss per common share basic | -0.09 | |||
| Net loss per common share diluted | -0.09 | |||
| Weighted-average common shares outstanding basic | 11,328,122 | |||
| Weighted-average common shares outstanding diluted | 11,328,122 | |||